A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration

Rasmussen, Annette; Bloch, Sune Land; Fuchs, Josefine; Hansen, Louise K. H.; Larsen, Michael; laCour, M; Lund‐Andersen, Henrik; Sander, Birgit

doi:10.1016/j.ophtha.2013.05.018

Cited by 106 publications

(82 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patient expectations are influenced by fellow-eye status, the longevity of the course of treatment and the consequential burden of multiple attendances, investigations and invasive treatment delivery. 5,6 Furthermore, there is also the emerging issue of when to continue, discontinue or change treatment from one n-AMD therapy to another.…”

Section: Introductionmentioning

confidence: 99%

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku

Chakravarthy

Gale

et al. 2015

Eye

272

227

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku

Chakravarthy

Gale

et al. 2015

Eye

272

227

View full text Add to dashboard Cite

“…66,67 Reviews of clinical trials and patient charts to determine the safety of AMD intravitreal therapies have found that incidence rates for endophthalmitis range from 0 to 0.16%. [68][69][70][71][72][73] A longitudinal study by Rasmussen et al 29 showed that of 600 eyes that began AMD intravitreal treatment, a third of the eyes still were receiving treatment after 4 years with no change in visual activity. 29 For 7584 injections given (average of 5.5 injections per year), two eyes were diagnosed with endophthalmitis, one eye with retinal detachment; no major hemorrhage or traumatic cataracts were observed.…”

Section: Discussionmentioning

confidence: 99%

“…[26][27][28] A study of over 500 patients receiving intraocular injections to treat AMD showed that 31% of these patients were still receiving injections 4 years later, and showed no loss of visual acuity and very few ocular complications over this time frame. 29 Recently, nanoparticles have been used for targeted drug delivery in chemotherapeutics and their use in the treatment of other diseases, such as Alzheimer's disease, inflammatory intestinal disease, and lupus, has been promising. [30][31][32][33][34][35] Given the issues with patient compliance in glaucoma, the use of nanoparticles to deliver a controlled, sustained release of therapeutics to the retina or other ocular structures via topical drops, contact lenses, and intravitreal injection could drastically reduce the number of patients who have progression to vision loss in this disease.…”

Section: Introductionmentioning

confidence: 99%

Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure

Lambert

Carlson

Ende

et al. 2015

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose: We examined the efficacy of an extended-release drug delivery system, nanosponge (NS) encapsulated compounds, administered intravitreally to lower intraocular pressure (IOP) in mice.Methods: Bilateral ocular hypertension was induced in mice by injecting microbeads into the anterior chamber. Hypertensive mice received NS loaded with ocular hypotensive drugs via intravitreal injection and IOP was monitored. Retinal deposition and retinal ganglion cell (RGC) uptake of Neuro-DiO were examined following intravitreal injection of Neuro-DiO-NS using confocal microscopy.Results: Brimonidine-loaded NS lowered IOP 12% to 30% for up to 6 days (P , 0.02), whereas travoprost-NS lowered IOP 19% to 29% for up to 4 days (P , 0.02) compared to saline injection. Three bimatoprost NS were tested: a 400-nm NS and two 700-nm NS with amorphous (A-NS) or amorphous/crystalline (AC-NS) crosslinkers. A single injection of 400 nm NS lowered IOP 24% to 33% for up to 17 days compared to saline, while A-NS and AC-NS lowered IOP 22% to 32% and 18% to 26%, respectively, for up to 32 days (P , 0.046). Over time retinal deposition of Neuro-DiO increased from 19% to 71%; Neuro-DiO released from NS was internalized by RGCs.Conclusions: A single injection of NS can effectively deliver ocular hypotensive drugs in a linear and continuous manner for up to 32 days. Also, NS may be effective at targeting RGCs, the neurons that degenerate in glaucoma.Translational Relevance: Patient compliance is a major issue in glaucoma. The use of NS to deliver a controlled, sustained release of therapeutics could drastically reduce the number of patients that progress to vision loss in this disease.

show abstract

“…Despite this, other studies show higher frequency of ranibizumab injection. Annette Rasmussen et al [11] adduced the number of injections over 4 years was 22.1. Giuseppe Querques et al [12] showed the number of intravitreal ranibizumab injections was 5.10 ± 2.05 injections over a 12-month follow-up.…”

Section: Discussionmentioning

confidence: 99%

Neovaskulinės amžinės geltonosios dėmės degeneracijos gydymo ranibizumabu 24 mėnesių morfologiniai ir funkciniai pokyčiai

Balčiūnienė¹,

Lažaunykaitė²

2015

Medicinos Teorija Ir Praktika

View full text Add to dashboard Cite

abstract:Key words: ranibizumab, age-related macular degeneration, central macular thickness. Research objective. To evaluate influence of treatment with vascular endothelial growth factor inhibitor, ranibizumab, for best corrected visual acuity and central macular thickness in patients with neovascular age-related macular degeneration. Materials and methods. In this retrospective study were included treatment -naive patients. Intravitreal injections were performed at Lithuanian University of Health Sciences Kaunas Clinics Eye clinic. In this study were analysed the 24-month morphological and functional outcomes of intravitreal ranibizumab injections. Best corrected visual acuity was meassured using the Snellen chart (Landolt's rings C optotypes). Optical coherence tomography images were obtained using the spectral -domain OCT (NIDEK RS -3000 Advance (NIDEK CO LTD, Japan). The central thickness measurements were obtained from macular thickness maps using the digital caliper tool. Results. In this study were included 88 patients. Best corrected visual acuity before treatment was 0.36 ± 0.22. The difference between visual acuity before and after first injection was 0.04 ± 0.22 (p = 0.03). Before fifth injection visual acuity was 0.41 ± 0.21, after -0.46 ± 0.22 (p = 0.05). Central macular thickness before treatment was 297.81 ± 106.04 µm. The difference between central macular thickness before and after first injection was 85.21 ± 113.37 µm (p < 0.001). Before second injection central macular thickness was 273.57 ± 87.49 µm, after -234.51 ± 58.96 µm (p = 0.002). Before fourth injection central macular thickness was 237.20 ± 40.87 µm, after -219.10 ± 42.26 µm (p = 0.04). The mean central macular thickness significantly decreased from 298.15 ± 104.78 to 229.08 ± 56.57 (p < 0.001). In 24 month of treatment the average number of ranibizumab injections was 3.61 ± 1.55. Conclusions. Our study's results showed that over 24 month best corrected visual acuity improvement was statistically significant after first and fifth injection. Baseline compared with last injection, there was not statistically significant difference. Central macular thickness improvement statistically significant was after first, second and fourth injection. There was statistically significant decreased baseline compared with the last injection. The mean number of ranibizumab injections was 3.61 ± 1.55 in 24 month. INTRODUCTIONAge-related macular degeneration (AMD) is the prevalent cause of moderate and severe vision loss in developed countries and the third major cause of blindness worldwide [1]. AMD is a disorder of unknown cause and pathogenesis causing decrease or loss of the ability to read in the elderly age-group and affecting about 180 million people all over

show abstract

A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration

Cited by 106 publications

References 23 publications

Defining response to anti-VEGF therapies in neovascular AMD

Defining response to anti-VEGF therapies in neovascular AMD

Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure

Neovaskulinės amžinės geltonosios dėmės degeneracijos gydymo ranibizumabu 24 mėnesių morfologiniai ir funkciniai pokyčiai

Contact Info

Product

Resources

About